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Human glucose-6-phosphate dehydrogenase: the crystal
structure reveals a structural NADP+ molecule and provides
insights into enzyme deficiency
Shannon WN Au1,2, Sheila Gover1, Veronica MS Lam2 and Margaret J Adams1*
Background: Glucose-6-phosphate dehydrogenase (G6PD) catalyses the first
committed step in the pentose phosphate pathway; the generation of NADPH by
this enzyme is essential for protection against oxidative stress. The human enzyme
is in a dimer↔tetramer equilibrium and its stability is dependent on NADP+
concentration. G6PD deficiency results from many different point mutations in the
X-linked gene encoding G6PD and is the most common human enzymopathy.
Severe deficiency causes chronic non-spherocytic haemolytic anaemia; the usual
symptoms are neonatal jaundice, favism and haemolytic anaemia.
Results: We have determined the first crystal structure of a human G6PD (the
mutant Canton, Arg459→Leu) at 3 Å resolution. The tetramer is a dimer of
dimers. Despite very similar dimer topology, there are two major differences
from G6PD of Leuconostoc mesenteroides: a structural NADP+ molecule,
close to the dimer interface but integral to the subunit, is visible in all subunits
of the human enzyme; and an intrasubunit disulphide bond tethers the
otherwise disordered N-terminal segment. The few dimer–dimer contacts
making the tetramer are charge–charge interactions. 
Conclusions: The importance of NADP+ for stability is explained by the
structural NADP+ site, which is not conserved in prokaryotes. The structure
shows that point mutations causing severe deficiency predominate close to the
structural NADP+ and the dimer interface, primarily affecting the stability of the
molecule. They also indicate that a stable dimer is essential to retain activity
in vivo. As there is an absolute requirement for some G6PD activity, residues
essential for coenzyme or substrate binding are rarely modified.
Introduction
The housekeeping enzyme glucose-6-phosphate dehydro-
genase (G6PD) catalyses the conversion of glucose-6-phos-
phate (G6P) to 6-phosphoglucono-δ-lactone with the
concomitant reduction of NADP+. This reaction is the first
and rate-limiting step in the pentose phosphate pathway.
The NADPH generated has been shown to be essential for
the protection of cells against oxidative damage [1,2]. This
role of the enzyme is particularly important in erythrocytes
where G6PD catalyses the major reaction providing the
reducing equivalent. Recent reports have suggested that
G6PD exerts its protective effect by providing NADPH to
maintain the intracellular level of reduced glutathione
[3,4]. NADPH, generated by increased G6PD activity, is
essential for regulating the optimum pH required for the
stimulation of cell growth by epidermal growth factor or
platelet-derived growth factor [5,6].
The monomer of human G6PD consists of 514 amino acids
with a calculated molecular weight of 59 kDa [7] (the con-
vention used here and in most published papers on this
enzyme is that the N-terminal methionine is designated
‘1’). The presence of tightly bound NADP+ in the human
erythrocyte enzyme and the effects of oxidised and
reduced coenzyme and pH on stability and oligomerisation
have been reported over many years [8–12]. The active
human enzyme exists in a dimer↔tetramer equilibrium.
High pH and ionic strength shift the equilibrium towards
the dimer, whereas low pH conditions cause a shift towards
the tetramer [8]; inactive monomers might also be formed
at high pH. Electron micrographs show that tetramers pre-
dominate below pH 6 and dimers predominate above pH 8
[13]. In addition EDTA, NADPH and G6P each favour
disruption of the dimer, whereas NADP+ or certain metal
ions favour the tetramer [9–12]. Little is known about the
physiological significance of the interconversion.
A multiple alignment of the 35 currently known G6PD
amino acid sequences [14] shows over 30% identity
between the human sequence and those of other species.
Two conserved sequence motifs were apparent in the
alignment: the completely conserved eight-residue
peptide RIDHYLGK (residues 198–205; single-letter
amino acid code) corresponding to the substrate-binding
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site [15–17]; and the dinucleotide-binding fingerprint
GxxGDLx (residues 38–44). Three-dimensional structure
analysis [18], kinetic studies [19] and site-directed muta-
genesis of the dimeric Leuconostoc mesenteroides G6PD
[20,21] have been used to elucidate the substrate- and
coenzyme-binding sites.
G6PD deficiency is the most common human enzymo-
pathy and affects 400 million people worldwide. The clini-
cal symptoms associated with deficiency are haemolytic
anaemia, favism, neonatal jaundice and, in severe (class I)
deficiency, chronic non-spherocytic haemolytic anaemia
(CNSHA). G6PD deficiency is genetically polymorphic; at
least 125 mutants have been detected at the molecular
level ([22] and references therein) and there are examples
of the same mutation arising independently in different
populations [23]. The gene is X-chromosome-linked and
there is evidence that heterozygotes have some protection
from malaria [24]. Of the known mutations, 60 are associ-
ated with class I deficiency; although the biochemical
properties of these mutations have been characterised,
only structural information can allow the correlation of
genotype with phenotype. The three-dimensional struc-
ture of L. mesenteroides G6PD enabled a dimeric human
homology model to be built which gave some insight into
the mechanism of deficiency [25]. In particular, a concen-
tration of class I mutation sites were anticipated at the
dimer interface.
The mutant studied in this report, G6PD Canton
Arg459→Leu (R459L), is one of the most common
Chinese variants. The mutant causes severe deficiency
without CNSHA and is thus placed in class II. In Hong
Kong and Southern China, where 4–6% of the male popula-
tion are G6PD deficient, it accounts for nearly 35% of these
cases [26,27]. Here, we present the first crystal structure of
human G6PD, that of G6PD Canton R459L, and discuss
its implications for the molecular basis of G6PD deficiency.
Results and discussion
The three-dimensional structure of human G6PD
Overall structure
Crystals of human G6PD Canton R459L grow at pH 5.8 in
the presence of NADP+. The space group of these crystals
is P212121 with eight monomers (tetramers ABCD and
EFGH) in each asymmetric unit. The structure was deter-
mined by molecular replacement using the large
β + α domains of the L. mesenteroides G6PD dimer as a
starting model [14]. This refinement used data to 3 Å reso-
lution, with noncrystallographic symmetry (NCS)
restraints for almost all residues of the β + α domain and
most residues of the coenzyme domain (see the Materials
and methods section). Sidechains have been positioned for
89% of residues; those that are disordered include residues
in the N-terminal segment, ten residues at the extremes of
the coenzyme domain and four residues at the C terminus
(see header records to Protein Data Bank [PDB] entry
1QKI). The dimer and tetramer interfaces are the same in
each tetramer of the asymmetric unit — AB, AC and AD
being equivalent to EF, EG and EH, respectively.
The monomer shows very similar topology to that of
L. mesenteroides G6PD [18]. The coenzyme-binding
domain (residues 31–200) adopts a classic β–α–β dinu-
cleotide-binding fold with the fingerprint sequence
GASGDLA at the tight turn following the first β strand.
The β + α domain (residues 201–515) is dominated by a
curved nine-stranded antiparallel β sheet. Glycollate ions,
a prerequisite for well-ordered crystals, exert their stabilis-
ing effect by binding in the active-site cleft between
domains, interacting with either His201 or Lys205 of the
conserved peptide RIDHYLGK. Lys205 has been shown
to be essential for catalysis in human G6PD [17] and the
residue equivalent to His201 is important for substrate
binding in the L. mesenteroides enzyme [19,21].
The extensive dimer interface (Figure 1) is between the
β + α domains of subunits A and B. Formation of the
dimer buries 13% of the total monomer surface, 2856 Å2,
and involves some 57 residues, 31 of which are hydropho-
bic. These residues are not highly conserved although the
geometry of the interface is similar in the two known
structures. Hydrophilic and charged contacts include main
chain hydrogen bonds from each Asp421 which join the
two βN strands of the β sheets. Ιn each dimer interface
there are also four salt bridges from Glu206 to Lys407 and
Glu419 to Arg427; only Lys407 is completely conserved.
The tetramer of human G6PD (Figure 2) has 222 noncrys-
tallographic symmetry. The surface area buried on
forming the tetramer from two dimers is only 706 Å2 per
monomer. Of the 15 residues involved, 11 are charged.
Four salt bridges, from Lys275 to Glu347 and from
Glu287 to Lys290, connect subunits A and D; an equiva-
lent set connect subunits B and C. The first 30 residues of
the N-terminal segment are disordered and do not have a
role in forming the tetramer seen here. The tetramer
interface contains some molecules of the cryo-protectant
glycerol but no NADP+. The electrostatic nature of the
tetramer contacts explains the sensitivity of the
dimer↔tetramer equilibrium to pH and ionic strength,
and shows human G6PD to be a dimer of dimers, in agree-
ment with earlier biochemical analysis [8–12].
The bound NADP +
Well-ordered NADP+ has been found in the β + α domain,
bound between the β sheet and the C terminus of each
subunit (Figure 3a); none of its atoms is within 16 Å of the
active site. The nature and position of binding suggest this
NADP+ is of structural importance and not the coenzyme.
The NADP+ is 77% buried in the protein, occupying a
crevice with a surface that is 50% hydrophobic and 50%
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hydrophilic; the binding site is overwhelmingly positively
charged. There is no dinucleotide fingerprint sequence
and contacts to the protein, shown in Figure 3b, are all
made to sidechain atoms of one subunit. The aromatic
rings of NADP+ are sandwiched between delocalised
pi-electron clouds; the adenine lies between Tyr503 and
Arg487 and the nicotinamide between Trp509 and
Tyr401. The 2′-phosphate makes hydrogen bonds to
Arg487, Arg357, Lys238 and Lys366; the bisphosphate
interacts with another arginine (Arg370) while Arg393 and
Asp421 interact with the amide function of the nicotin-
amide. The role of Arg487 is typical of NADP+-binding
sites in several enzymes [28]. The nicotinamide ring is
completely buried with no access for hydride transfer.
Each NADP+ is bound entirely within one subunit,
however, it is 14 Å from its equivalent in the dimer and
only 7 Å from protein residues of the second subunit. One
of the NADP+ ligands, Asp421, is at the centre of the
dimer interface; it is clear that removal of NADP+ would
affect subunit association as well as the conformation of
the subunit itself.
The N-terminal region and disulphide bridge
Continuous density was not observed for the first
30 residues of human G6PD, even when the solvent level
for density modification was lowered or a higher sphere
radius was used to create the protein mask. Electron
density continuous with the sidechain of Cys446, a residue
not far from the N-terminal segment, was, however, seen
in the averaged electron-density map and longer stretches
of density were observed after NCS constraints were
removed. It has proved possible to build a polyalanine
chain into this density for three to seven residues in all
subunits; a disulphide bridge to Cys13 is clear in subunits
C, D, E, F and H. The N-terminal segments built do not
obey the noncrystallographic symmetry and none make
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Figure 1
A dimer of human G6PD viewed down the
twofold axis. In subunit A helices are coloured
pink and β strands are blue; in subunit B
helices and strands are green and orange,
respectively. Secondary structure elements
are labelled in subunit A. Structural NADP+
molecules are drawn in dark blue in ball-and-
stick mode. The dinucleotide-binding
fingerprint and conserved peptide are
highlighted in purple. The Cα atoms of some
residues discussed in detail in the text are
drawn as magenta spheres in subunit B.
These are Pro172 (cis/trans conformation),
Cys446 (disulphide bridge), Arg459 (mutation
site of Canton variant), and Glu206, Lys407,
Glu419 and Arg427 (involved in salt bridges
at the dimer interface). The N-terminal
residues 1–26 are not shown. (The figure was
prepared using BOBSCRIPT [42,43] and
RASTER3D [44,45].)
Figure 2
The G6PD tetramer. (a) Tetramer ABCD
shown with the long tetramer axis running
vertically into the plane of the page. The four
subunits A, B, C and D are shown in blue,
orange, green and pink, respectively.
Structural NADP+ molecules are drawn in
dark blue in ball-and-stick mode. (b) The salt
bridge residues linking subunits B and C
drawn in the same orientation as Figure 3a
and coloured by atom type: carbon, grey;
oxygen, red; nitrogen blue. (The figure was
prepared using BOBSCRIPT [42,43] and
RASTER3D [44,45].)
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further contact with the rest of the tetramer; nor could
they reach the tetramer interface. It is suggested that
these residues are probably all disordered unless the disul-
phide bridge is formed. 
None of the six other cysteine residues within the
subunit could form a disulphide bridge in the active mol-
ecule. Mutants in which either Cys13 or Cys446 is
replaced by glycine have low activity [29], but a mutant
in which the first 25 N-terminal residues have been
deleted shows nearly normal enzyme activity and
increased thermostability [14]. It seems likely that the
bridge prevents the mobile N-terminal segment from
interfering with the dimerisation or catalytic activity of
the enzyme. Therefore, although Cys446 is highly acces-
sible in the absence of a disulphide bridge, it does not
necessarily form incorrect disulphide bridges and inacti-
vate the enzyme.
Cis or trans Pro172 and the coenzyme-binding site
In the averaged map, the mainchain conformation
extending ten residues from the conserved triplet Glu-
Lys-Pro (residues 170–172) was a good fit to that in
subunit B of the L. mesenteroides apoenzyme, where the
corresponding proline (Pro149) is in a trans conformation,
and a poor fit to that of subunit A, where Pro149 is cis. On
relieving NCS constraints, subunit E of human G6PD
was seen to differ from the other seven subunits and
showed a better fit to the trace corresponding to a cis
proline (Figure 4). There is some residual disorder in this
region, which in the other subunits is well ordered. The
predominance of trans Pro172 in the human enzyme con-
trasts with the L. mesenteroides enzyme, where in all binary
and ternary complexes Pro149 is cis (PDB entry code
2DPG, other structures to be published) and the single
subunit seen with the trans isomer has a mobile coen-
zyme-binding domain [18]. The changes in the conforma-
tion of residues of helix αe that result from the presence
of a cis or trans proline modify some features of the active-
site cleft. The proline residue is the site of a class I muta-
tion [30] (discussed later). 
On the basis of the structure of L. mesenteroides G6PD, and
in light of the conservation in all known G6PD sequences
of a coenzyme-binding fingerprint and an arginine (Arg72
in the human enzyme), a common coenzyme-binding site
at the C terminus of the β sheet of the coenzyme-binding
domain is expected. Kinetic and structural analyses of site-
directed mutants have demonstrated that the guanidine
group of the equivalent arginine (Arg46) of L. mesenteroides
G6PD binds the 2′-phosphate of NADP+ and has a critical
role in the coenzyme specificity [20]. Although NADP+
was added at all stages of the purification and crystallisa-
tion of the human enzyme and the structural NADP+ mol-
ecule has been found, there is little evidence of binding at
the fingerprint peptide. Difference electron density at the
4σ level near Arg72 of subunit E might indicate that
NADP+ is sometimes bound. It may be significant that
Pro172 is in the cis conformation in this subunit. The
coenzyme is not well defined in the 3 Å resolution map
and, if bound, is highly disordered. 
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Figure 3
The structural NADP+ site. (a) The Fo–Fc difference map for NADP+
contoured at 2.8σ. The NADP+ molecule is shown in orange in ball-
and-stick mode. The secondary structure elements are labelled. The
colour scheme for the sheets and helices is the same as in Figure 1.
(b) Ring stacking and hydrogen-bond interactions with the NADP+
molecule. Hydrogen bonds are shown as green dotted lines. Residues
in the binding cleft are coloured by atom type as described in Figure
2b. In order to show the NADP+ clearly, its carbon atoms are in yellow
and phosphorus atoms are in purple. The orientation is the same as in
(a). (The figure was prepared using BOBSCRIPT [42,43] and
RASTER3D [44,45].)
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G6PD deficiency and the three-dimensional structure
It has long been important to understand the relationship
between the biochemical characteristics of G6PD defi-
ciency and its molecular basis; the present 3 Å structure
extends our understanding beyond that given by the
homology model [25]. The large number of mutation sites
(currently 127) has always suggested a variety of mecha-
nisms for deficiency. Discussion will focus on the varied
ways in which the 60 known class I mutations might
account for differing protein stability or activity. Clearly,
even with severe deficiency, the enzyme remains viable so
the structural changes leading to lower stability or activity
will be small. The requirement for viable enzyme makes
it extremely unlikely that residues essential for activity or
those which contribute most to coenzyme or substrate
binding will be modified.
Probable reasons for decreased viability and thermostabil-
ity of known class I variants are tabulated in the supple-
mentary material, where variants are described both by
their mutation site and by name. The human homology
model suggested the locations of a range of class I vari-
ants and these are almost all confirmed by the present
structure. As predicted, the variants involving two and
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Figure 4
Stereoview of the 2Fo–Fc electron density
around Pro172, contoured at 0.95σ.
(a) Trans Pro172 in subunit A. (b) Cis
Pro172 in subunit E, with the trans Pro172
of subunit A superimposed in green. The
orientation is the same as in (a). Atoms are
coloured as in Figure 2b. (The figure was
prepared using BOBSCRIPT [42,43] and
RASTER3D [44,45].)
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seven residue deletions (‘Stonybrook’ and ‘Nara’) remove
external loops.
Class I mutations at the dimer interface and close to the
structural NADP+
Early work reviewed by Levy [31] indicated varying
NADP+ stoichiometry, finding a minimum of four and a
maximum of eight binding sites per tetramer. Hirono et al.
[32], observing that several molecules containing class I
mutations in exon 10 could be reactivated by an increased
NADP+ concentration, suggested that the structural and
coenzyme NADP+ sites might be the same. In retrospect,
the small effects on the observed Km for NADP+ (at most
fourfold) argued against these residues being directly impli-
cated in binding at the coenzyme site. The homology model
clearly ruled out this possibility showing the cluster of exon
10 mutations to be close to the dimer interface; integrity of
the dimer and thus of the interface is essential for activity. 
The X-ray structure gives added significance to mutations
near the dimer interface, because although the structural
NADP+ is within each individual subunit it is close to the
interface (Figure 5a). The few tetramer contacts are close
to a different part of the dimer interface. Of the class I
mutations, 26 are in, or close to, the dimer interface and 14
are close to the structural NADP+ molecule. The muta-
tions E389G, R393G, R393H, V394L and E398K fall into
both categories, whereas E274K is at the tetramer inter-
face. The structure allows us to see the way contacts are
likely to be influenced by the mutations. Hydrophobic
contacts, hydrogen bonds and salt bridges are disrupted;
buried groups replaced by larger ones must force different
mainchain conformations. Examples include the incorpo-
ration of a larger or smaller group (e.g., V213L, G410C and
F216L), the substitution of oppositely charged residues
(e.g., E274K, K386E and E416K), or the loss of a charge
(e.g., R387C and R439P). 
The mutation sites K386E and R387H immediately
precede the β sheet strand βL; the mainchain atoms are at
the dimer surface but the sidechains do not make inter-
subunit contacts. These variants are sensitive to low
NADP+ concentrations, although the mutation site is 8 Å
from the structural NADP+. The differently charged or
shaped sidechains must modify the mainchain conforma-
tion, affecting the dimer interface. The intimate relation-
ship between stability and NADP+ concentration arises
because βL, βM and βN act as a scaffold for both the
interface and the residues binding NADP+. The class I
mutations in sheet strands βM and βN, M405I and
E416K, are of residues that form part of the dimer surface
at the end of the sheet distant from the NADP+. Here
both sidechain and mainchain atoms make dimer contacts
that will be disrupted by mutations. The mutations
G410C and G410D in the βM–βN turn are also in the
dimer surface (Figure 5b). The larger residues are steri-
cally hindered and the low thermostability of these vari-
ants can be explained by the failure to retain the required
mainchain conformation when glycine is replaced.
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Figure 5
Class I mutations at the dimer interface and close to the structural
NADP+ site. (a) Helices and sheets are drawn as coils using the same
colour scheme as in Figure 1. The red and yellow spheres indicate the
mutations in subunits A and B, respectively. The structural NADP+
molecules in both subunits are drawn in dark blue in ball-and-stick
mode, as are the sidechains of the Asp421 residues. (b) Variants
‘Shinagawa’ G410D, Tokyo E416K, ‘Georgia’ Y428 STOP, and
Sumare V431G at the dimer interface shown in stick mode. The
carbon atoms of the mutated residues are shown in magenta and were
modelled using the program O [37]. The colour scheme for subunits A
and B is the same as in (a). The salt bridge linking Asp416 and Lys408
is drawn as a black dashed line with its length given in Å. The steric
clash predicted after replacing Gly410 with aspartate is highlighted by
the distances shown in red. (The figure was prepared using
BOBSCRIPT [42,43] and RASTER3D [44,45].)
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The X-ray structure identifies a group of class I variants
with mutations of residues that bind the structural NADP+
directly: the shorter arginine of K238R will make a less
favourable contact with the 2′-phosphate; and the histidine
of R393H would make poorer interactions with the NADP+
(Figure 3b) than the arginine (this variant can be reactivated
by the addition of NADP+ [33]). The class I variants G488S,
G488V and P489L in the βO–αo turn demonstrate the
importance of the conformational properties of glycine and
proline in positioning Arg487 to interact with the adenine
and the 2′-phosphate. The rare mutation in Bangkok Noi,
F501C, changes the size of a residue which is a part of the
NADP+-binding pocket but not part of the dimer interface.
Site-directed mutagenesis based on predictions from the
homology model has focused on the dimer interface [12].
Mutation of Asp421 (Figure 5a) to a neutral residue
(D421A or D421N) increases thermostability and decreases
the dependence on NADP+, whereas mutation to a posi-
tively charged residue (D421K or D421R) further enhances
stability. Although the structure upholds the prediction
that substitution of a positive residue at 421 would tighten
the dimer interface through contacts with neighbouring
aspartates and glutamates, it also shows that  the carboxyl
group of Asp421 contacts the nicotinamide amide
(Figure 3b). Lysine or arginine would not make this contact
correctly and their proximity to the charged pyridinium
ring would be unfavourable. Again the interplay of the
structural NADP+ and the dimer interface in stabilising the
active conformation of the human enzyme is demonstrated.
G6PD Volendam P172S and other class I variants in the
coenzyme-binding domain 
The location of Pro172 has already been discussed. The
βE–αe loop forms part of the active-site cleft and the
importance of this conserved residue has been shown in
L. mesenteroides G6PD where the engineered mutant
P149G shows a 20-fold increase in Km and a 30-fold
decrease in kcat for G6P in both NADP+- and NAD+-
linked reactions (HR Levy, personal communication).
Recently, the kinetic properties of engineered human
G6PD carrying the P172S mutation have been analysed:
there is a fourfold increase in Km for both NADP+
and G6P [30]. It seems probable that the conformation
of Pro172 is important for coenzyme binding; the
cis/trans isomerism is predicted to be involved in the
enzyme mechanism. 
Only 12 other class I mutations involve residues in the
coenzyme-binding domain; these mutations are concen-
trated in the parallel β sheet and in helix αe. Disruption of
the sheet by a deletion, such as ∆I35 in βA, will have an
impact on NADP+ binding in the coenzyme site at the end
of the β sheet strands.
Mutations close to the disulphide bridge
There are three known mutations of residues adjacent to
the 13–446 disulphide bridge. G447R is a class I mutation;
it is unlikely that the bridge could form without the small
and flexible glycine in this position at the end of helix
αm. The mutation G14R adjacent to Cys13 in the less
structured N-terminal segment has less effect than the
same mutation at position 447; the variant is classified as
class II or the milder class III, suggesting the steric
requirements at this end of the disulphide bridge are less
severe. Similarly, the recently characterised class III
variant V12L [34] shows that a mutation to a similar
residue in the disordered N-terminal region is unlikely to
affect the bridge greatly and has much less significance
for enzyme stability.
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Figure 6
A comparison of the surface potential in
human and L. mesenteroides G6PD.
(a) Potential surface of the structural NADP+
site in human G6PD. The locations of some
of the residues in the NADP+ site are
labelled. The atoms of NADP+ are coloured
by type (carbon is yellow, oxygen red,
nitrogen blue and phosphorus green). 
(b) Potential surface of L. mesenteroides
G6PD in the same region with the structural
NADP+ of the human enzyme superimposed
in green. Residues 344, 372, 382, 465 and
471 in the L. mesenteroides enzyme
structurally align with residues 366, 393,
403, 487 and 493, respectively, in the
human enzyme. Residue Gly485 at the 
C terminus of the L. mesenteroides enzyme
is also labelled. In both diagrams, the surface
is colour-coded according to electrostatic
potential on a scale from –10 to +10, where
blue and red areas represent positively and
negatively charged regions, respectively.
(The figures were generated using the
program GRASP [46]).
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Class II mutations: G6PD Canton R459L and G6PD Kaiping
R463H
Because the human G6PD structure was determined from
G6PD Canton R459L crystals, the effect of replacing the
arginine of the wild-type enzyme with leucine should be
considered. Crystals of normal human G6PD, named G6PD
B, have been grown that are isomorphous with those of
G6PD Canton. These crystals were too fragile for a full data
set to be collected, but the G6PD Canton tetramer proved a
successful search model for the partial data obtained (CE
Naylor, personal communication). The mutation R459L
does not, therefore, have a major effect on the overall fold. 
The R459L mutation is located in the surface helix αn,
where there is enough space for either sidechain and no
partner for a salt bridge. A comparison with the three-
dimensional structure of the deletion mutant ∆G6PD [14],
which contains an arginine residue at position 459, shows
that the mainchain conformation of αn is not affected by
the change to leucine. The reason for an observed twofold
reduction of the Km for G6P [26], even though 459 is far
from the active site, may relate to its proximity to Trp462,
on the same helix, which does approach the active-site
cleft. The substitution of a hydrophobic residue at the
surface of the molecule has been of unexpected crystallo-
graphic benefit. The Leu459 sidechains of subunits A and
E are each involved in contacts between the two indepen-
dent tetramers in the P212121 crystals and enhance their
stability over those of the wild-type enzyme. In contrast,
the mutation R463H, in the next turn of αn, would disrupt
a salt bridge formed with Glu460 in the same helix. It has
not proved possible to crystallise G6PD Kaiping R463H
under the conditions used for G6PD Canton.
G6PD of other species and a molecule structurally related to
G6PD
The major difference between the two G6PDs of known
structure is the lack of a structural NADP+ site in the
L. mesenteroides enzyme. There is little sequence conserva-
tion of the binding site between the two species. The
folds at the C termini differ: the human enzyme has 20
residues compared with ten for L. mesenteroides. A cleft
lined with positively charged residues is formed for
human G6PD, whereas the L. mesenteroides enzyme has no
cleft  and the surface is overwhelmingly negatively
charged, repelling any NADP+ molecule (Figure 6).
Inspection of the 35 known G6PD sequences cited by
Au et al. [14] suggests that the structural NADP+ site is
conserved in rat, mouse, wallaroo, the fish Fugu rubripes,
and  fruit flies (Figure 7). Yeast enzymes show two con-
servative substitutions and the soluble enzyme from
potato also contains two substitutions, one of which is
conservative, suggesting that the site may also be
retained in these species. An increasing number of
replacements occur in prokaryotic enzymes and the
C-terminal tail is shortened. It is likely that these
G6PDs, in common with the L. mesenteroides enzyme,
have no structural NADP+ site. 
A second important difference is the dimer↔tetramer
equilibrium in human G6PD and the absence of a
tetramer for the L. mesenteroides enzyme. The residues
forming the salt bridges in the tetramer are well con-
served: Glu287 and Lys290 are present in 30 species. In
L. mesenteroides G6PD there would be no salt bridge as
both of these residues (264 and 267) are alanine. In
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Figure 7
Sequence alignment around the human G6PD binding site for structural
NADP+. The four groups containing human, Caenorhabditis elegans,
Nicotiana tabacum and L. mesenteroides are successively less likely to
retain the site. The figure to the left of the species name indicates the
number of equivalent sequences in the sample of 35 aligned (see text),
dashed lines show the evolutionary tree, plus signs indicate connection
points. Binding residues are shown in green and conservative
replacements are in grey. Residues conserved in all species are in blue;
residues conserved in all species but one are in violet.
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Aspergillus niger and Emericella nidulans, the residue equiv-
alent to 290 is arginine; in the absence of any rigid
secondary structure at the tetramer interface this substi-
tution is likely to have only a small effect. The second
salt bridge Lys275–Glu347 is less well conserved. Both
residues are conserved in G6PD from animals, F. rubripes
and fruit flies; in some yeasts an arginine replaces the
lysine. The salt bridge would be retained in the soluble
enzyme of Solanum tuberosum (the potato) but not in the
plastid enzyme. The bacterial enzymes commonly have
two hydrophobic residues in these positions and in L.
mesenteroides they are lysine and proline; thus the L. mesen-
teroides enzyme is the only form in which neither salt
bridge can be made.
Structural comparisons have shown a previously unexpected
equivalence between the topology of the entire G6PD
monomer and that of glucose–fructose oxidoreductase
(GFOR) [35]. The subunit interactions of the two enzymes
are, however, very different. Both enzymes associate the
β + α domain sheets by means of hydrogen bonds between
the βN strands of two subunits. In G6PD, the AB dimer is
formed with many additional contacts between the two sub-
units; it is the only subunit interaction for the L. mesen-
teroides enzyme. In contrast, very few GFOR residues are
involved in the equivalent contact (between subunits A and
C). The resulting 18-stranded sheet forms a semicircle in
G6PD, whereas in GFOR it is flat. The most important
contact for GFOR, forming the AB dimer, is made by associ-
ating the concave faces of two sheets; this association is
blocked both by the C-terminal helix (αo) of G6PD and by
the extensions to βM and βN (Figure 8). The structural
NADP+ bound between αo and the sheet also prevents the
formation of this intersubunit contact in human G6PD.
Biological implications
Glucose-6-phosphate dehydrogenase (G6PD), as well as
being the first and rate-controlling enzyme of the
pentose phosphate pathway, is essential to generate
NADPH in response to oxidative stress. G6PD defi-
ciency is the most common human enzymopathy; to
date 127 different point mutations have been identified.
The most common symptom is haemolysis under oxida-
tive stress caused by infections and drugs. Low G6PD
activity is most apparent in erythrocytes, which have no
capacity for protein synthesis. The G6PD gene is
X-chromosome-linked and the wide dispersion of the
deficiency has been linked to the observation that het-
erozygotes acquire some protection against malaria.
Our 3 Å resolution structure, which shows human
G6PD for the first time, is of the Canton variant,
Arg459→Leu. A structural NADP+ molecule was
found in each subunit of the tetramer, distant from the
active site but close to the dimer interface. Bacterial
G6PD has no such structural NADP+ molecule. The
structure shows an intrasubunit disulphide bond
between the N-terminal segment of the enzyme and the
β + α domain. Tetramer interactions involve neither the
N-terminal segment nor the NADP+ molecule. 
To understand the molecular basis of G6PD deficiency,
and in order to correlate genotype with phenotype, the
many point mutations must be located in the three-
dimensional structure. Mutations causing severe defi-
ciency are concentrated close to the dimer interface and
the structural NADP+, indicating that the integrity of
these regions is important for enzyme stability and there-
fore for in vivo activity. In agreement with the require-
ment for residual G6PD activity for survival, we do not
observe mutations of residues directly implicated in the
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Figure 8
The association of subunits in G6PD and GFOR. (a) Overlap of the
β + α domain sheet of monomer A of G6PD (in green) with that of
monomer A of GFOR (in cyan). The contrast in the methods by which
this sheet is extended in the two enzymes is illustrated. (b) The G6PD
tetramer. (c) The GFOR tetramer with monomer A in the same
orientation as that of G6PD. The secondary structure elements
hindering the formation of a GFOR-like tetramer for G6PD are
indicated in red. (The figures were generated using BOBSCRIPT
[42,43] and RASTER3D [44,45].)
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active site. The mutation of a conserved proline residue
(Pro172) predicted to change conformation during catal-
ysis causes severe deficiency. The structure bridges the
gap between the clinical severity of G6PD deficiency and
mutations of the enzyme; it provides a secure basis for
site-directed mutagenesis aimed at understanding human
G6PD activity, stability and dependence on NADP+ con-
centration. 
Materials and methods
Recombinant human G6PD (Canton variant) crystallised at pH 5.8 from
buffer containing citrate (0.1 M) NADP+ (0.1 M) and glycollate (0.05 M)
with PEG 3350 precipitant. The space group is P212121, and the cell
dimensions of flash-frozen crystals with glycerol as cryoprotectant are
a = 128.9 Å, b = 208.7 Å, c = 214.3 Å, α = β = γ = 90°. Determination of
the structure, by molecular replacement using L. mesenteroides G6PD
as a search model, has been reported [14]. Phases were improved by
solvent flattening and histogram matching using the program DM [36].
The model was built into eightfold averaged maps using the program O
[37]. 2Fo–Fc maps were used to identify regions with different conforma-
tions in the eight subunits for exclusion from NCS restraints. Refinement
was carried out with version 3.851 of X-PLOR [38] and maps were cal-
culated using the CCP4 package [39]. In the first cycle, the R factor
dropped from 51.4% to 30.5% and the Rfree from 52.1% to 33.0% for a
model containing 83.5% of the human sequence and data between 8 Å
and 3.5 Å. The free R Factor (Rfree) is calculated for the 5% of reflections
which were omitted from the refinement for validation [40]. 
Superposition of the eight subunits in the asymmetric unit showed the
mainchain rms difference of the coenzyme domains to be about fivefold
greater than that of the β + α domains. This correlated with the differ-
ent intermolecular contacts of the coenzyme domains. Two groups of
NCS restraints (with a weight of 25 for the coenzyme domain (residues
31–200) and of 50 for the β + α domain (residues 201–511)) were
imposed for the subsequent refinement. 
Cycles of rebuilding, positional refinement, and simulated annealing
were continued until convergence. Clearer density for some of the car-
bonyl groups was seen in the averaged map after the phases were
extended to 3 Å. Intrasubunit disulphide bonds were built for subunits
C, D, E, F and H based on the continuous density observed to extend
between Cys446 and Cys13. Polyalanine chains could be built into the
map in this region, they ranged from three to seven residues and were
of a different conformation in each subunit.
These segments were excluded from the NCS restraints as were poorly
defined residues of the external βB–αb loop and helix αb, residues in
the vicinity of Pro172 and residues involved in intertetrameric contacts. 
Application of a bulk-solvent correction allowed the whole range of
observed reflections from 25–3 Å to be used in the refinement. In the
current structure, only electron-density peaks >3σ in difference maps
have been interpreted. Three strong peaks (>3.5σ) observed in the orig-
inal Fo–Fc map indicated the phosphate groups of the structural NADP+.
Only the most tightly bound solvent molecules have been included; there
are 55 forming potential hydrogen bonds to the protein. Five glycerol
molecules have been modelled at the tetramer interface and a glycollate
was built into every subunit, close to the Nε2 atom of the active-site
His201. The final R factor and Rfree are 24.7% and 29.4%, respectively.
Table 1 shows the statistics after this refinement. Ramachandran plots
produced by PROCHECK [41] show 83.8% of all residues in the most-
favoured regions and 15.0% in the additional allowed areas.
The rmsd of mainchain atoms on superposing the β + α domains of dif-
ferent subunits is 0.11 ± 0.02 Å. When coenzyme domains are super-
posed using the coenzyme domain transformation matrix, the rmsd is
0.46 ± 0.11 Å if subunit E is excluded. The coenzyme domain of subunit
E superposes on the remainder with an rmsd of 0.78 ± 0.08 Å. If the
large domain matrix is used to superpose the coenzyme domains of
subunits A, B, C, D, F, G and H, the rmsd is 0.83 ± 0.23 Å. These
results reflect the differing NCS restraints, the effect of cis Pro172 in
subunit E and small differences in orientation of the coenzyme domains.
Accession numbers
Coordinates and structure factors have been deposited with the
Protein Data Bank (accession codes 1QKI and R1QKISF). 
Supplementary material
Supplementary material including a list of GP6D class 1 variants and
possible mechanisms of deficiency is available at http://current-
biology.com/supmat/supmatin.htm.
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